Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $0.22.

  • Arrowhead Pharmaceuticals' EPS (Basic) rose 11582.73% to $0.22 in Q4 2025 from the same period last year, while for Dec 2025 it was $1.56, marking a year-over-year increase of 13023.26%. This contributed to the annual value of $0.23 for FY2025, which is 10442.32% up from last year.
  • Arrowhead Pharmaceuticals' EPS (Basic) amounted to $0.22 in Q4 2025, which was up 11582.73% from $0.12 recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' EPS (Basic) ranged from a high of $2.78 in Q1 2025 and a low of -$1.45 during Q3 2024
  • In the last 5 years, Arrowhead Pharmaceuticals' EPS (Basic) had a median value of -$0.65 in 2022 and averaged -$0.47.
  • In the last 5 years, Arrowhead Pharmaceuticals' EPS (Basic) plummeted by 32173.91% in 2024 and then surged by 37254.9% in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' EPS (Basic) (Quarter) stood at -$0.6 in 2021, then surged by 35.0% to -$0.39 in 2022, then crashed by 217.95% to -$1.24 in 2023, then fell by 12.1% to -$1.39 in 2024, then surged by 115.83% to $0.22 in 2025.
  • Its EPS (Basic) was $0.22 in Q4 2025, compared to $0.12 in Q3 2025 and -$1.26 in Q2 2025.